Insider filing · SNDX
Nicholas A.J. Botwood
Head of R&D, CMO
profile →
Syndax Pharmaceuticals, Inc.
SNDX · Healthcare · 11 filings in 24 months
ticker →
Nicholas A.J. Botwood sold $1.2M of Syndax Pharmaceuticals (SNDX)
Executed Jun 11, disclosed Jun 12, 1 day later.
Value, as filed
$1.2M
65,515 sh across 2 lots
Executed
Jun 11
the trade date, as filed
Disclosed
Jun 12
1 day after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
NBNicholas A.J. Botwood (Head of R&D, CMO) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Syndax Pharmaceuticals, Inc. (SNDX). The largest single filing was $1.2M of SNDX (65,515 sh across 2 lots, as filed), executed Jun 11.
The name
SNDXHealthcare · Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Nicholas A.J. Botwood in SNDX
SNDXPURCHASE
Syndax Pharmaceuticals, Inc.
$106K11,765 sh × $9.00
Exec May 16 2025
Filed May 19 2025 · 5:30 PM ET